eTable1: Top ten racial/ethnic categories used in the censuses of countries participating in phase III MS trials
For the countries that participated in phase III MS trials and report racial/ethnic
demographics in their national censuses, their top ten most prevalent racial and ethnic identities are listed. Racial and ethnic identities were obtained from UNdata (United Nations Statistics Division).
eReferences
e1. MS Treatment: AVONEX® (interferon beta-1a): Official Patient Site. Biogen. 2021.
Accessed October 5, 2021. https://www.avonex.com
e2. Official Healthcare Professional Site: AVONEX® (Interferon beta-1a). Biogen. 2021.
Accessed October 5, 2021. https://hcp.avonex.com
e3. Rebif® (interferon beta-1a) Relapsing Multiple Sclerosis (RMS) Treatment. EMD Serono. 2021. Accessed October 5, 2021. https://www.rebif.com
e4. Rebif® (interferon beta-1a) | Relapsing Multiple Sclerosis (RMS) | HCPs. EMD Serono. 2021. Accessed October 5, 2021. https://www.rebif.com/hcp/home.html e5. BETASERON® (interferon beta-1b) | Prescription medication. Bayer. 2021.
Accessed October 5, 2021. https://www.betaseron.com
e6. For Healthcare Professionals | BETASERON® (interferon beta-1b). Bayer. 2021.
Accessed October 5, 2021. https://www.betaseron.com/hcps
e7. EXTAVIA® - Multiple Sclerosis (MS) Treatment. Novartis Pharmaceuticals Corporation. 2021. Accessed October 5, 2021. https://www.extavia.com
e8. Multiple Sclerosis Treatment | EXTAVIA. Novartis Pharmaceuticals Corporation.
2021. Accessed October 5, 2021. https://www.extaviahcp.com
e9. Relapsing MS Treatment | PLEGRIDY® (peginterferon beta-1a). Biogen. 2021.
Accessed October 5, 2021. https://www.plegridy.com
e10. Relapsing MS Treatment | PLEGRIDY® (peginterferon beta-1a) | HCP Site.
Biogen. 2021. Accessed October 5, 2021. https://www.plegridyhcp.com
e11. COPAXONE® (glatiramer acetate injection) for Relapsing MS. Teva Neuroscience, Inc. Updated August 2021. Accessed October 5, 2021. https://www.copaxone.com e12. COPAXONE® (glatiramer acetate injection) HCP Site. Teva Neuroscience, Inc.
Updated March 2021. Accessed October 5, 2021. https://www.copaxonehcp.com e13. AUBAGIO® (teriflunomide): A Once-Daily Pill for Relapsing MS. Genzyme
Corporation. Updated May 2021. Accessed October 5, 2021. https://www.aubagio.com e14. AUBAGIO® (teriflunomide) | Official Healthcare Professional Site. Genzyme
Corporation. Updated May 2021. Accessed October, 2021.
https://www.aubagiohcp.com
e15. Pill for RRMS Treatment | GILENYA® (fingolimod). Novartis Pharmaceuticals Corporation. 2020. Accessed October 5, 2021. https://www.gilenya.com
e16. Relapsing-Remitting MS Treatment | GILENYA® (fingolimod) | HCP. Novartis Pharmaceuticals Corporation. 2021. Accessed October 5, 2021.
https://www.gilenyahcp.com
e17. Relapsing MS Progression Treatment | MAYZENT® (siponimod). Novartis Pharmaceuticals Corporation. Updated February 2021. Accessed October 5, 2021.
https://www.mayzent.com
e18. Progressing RMS Treatment | MAYZENT® (siponimod). Novartis Pharmaceuticals Corporation. Updated May 2021. Accessed October 5, 2021.
https://www.mayzenthcp.com
e19. MAVENCLAD® (cladribine) tablets. Merck KGaA. Updated July 2021. Accessed October 5, 2021. https://www.mavenclad.com
e20. MAVENCLAD® (cladribine) tablets: Now Approved | HCP. EMD Serono. Updated March 2021. Accessed October 5, 2021. https://www.mavenclad.com/en/hcp.html e21. Official Patient Website | Tecfidera® (dimethyl fumarate). Biogen. 2021. Accessed October 5, 2021. https://www.tecfidera.com
e22. Official HCP Homepage | Tecfidera® (dimethyl fumarate). Biogen. 2021. Accessed October 5, 2021. https://www.tecfiderahcp.com
e23. Relapsing MS Infusion Treatment: LEMTRADA® (alemtuzumab). Updated July 2021. Accessed October 5, 2021. https://www.lemtrada.com
e24. LEMTRADA® (alemtuzumab) | Healthcare Professional Site. Genzyme Corporation. Accessed October 5, 2021. https://www.lemtradahcp.com
e25. TYSABRI® (natalizumab) | Official Patient Website. Biogen. 2021. Accessed October 5, 2021. https://www.tysabri.com
e26. Official Physician Home page | TYSABRI® (natalizumab) HCP. Biogen. 2021.
Accessed October 5, 2021. https://www.tysabrihcp.com
e27. OCREVUS® (ocrelizumab) | Multiple Sclerosis (MS) Treatment. Genentech USA, Inc. 2021. Accessed October 5, 2021. https://www.ocrevus.com
e28. Relapsing MS and Primary Progressive MS Treatment | OCREVUS®
(ocrelizumab). Genentech USA, Inc. 2021. https://www.ocrevus.com/hcp
e29. ZEPOSIA (ozanimod) — One Pill, Once a Day. Bristol-Myers Squibb Company.
Updated June 2021. Accessed October 5, 2021. https://www.zeposia.com
e30. ZEPOSIA® (ozanimod) for MS and UC | Official HCP Website. Updated June 2021. Accessed October 5, 2021. https://www.zeposiahcp.com
e31. Patient Homepage | VUMERITY® (diroximel fumarate). Biogen. 2021. Accessed October 5, 2021. https://www.vumerity.com
e32. Official HCP Website | VUMERITY® (diroximel fumarate). Updated July 2021.
Accessed October 5, 2021. https://www.vumerityhcp.com
e33. Group TIMSSG and the U of BCMA. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277–
1285.
e34. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268–1276.
e35. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–294.
e36. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active
disease using MRI and clinical criteria. J Neurology Neurosurg Psychiatry. 1997;62:112.
e37. Ebers GC, Group P (Prevention of R and D by I β-1a S in MSS. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
e38. Kappos L, MS ESG on I β-1b in SP. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet.
1998;352:1491–1497.
e39. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis. New Engl J Med.
2000;343:898–904.
e40. Group SPECT of RI-B-1a in M (SPECTRIMS) S. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology.
2001;56:1496–1504.
e41. Comi G, Group the ET of MSS, Filippi M, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet.
2001;357:1576–1582.
e42. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS. Neurology. 2002;59:1496–1506.
e43. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet.
2002;360:2018–2025.
e44. Panitch H, Miller A, Paty D, Weinshenker B, MS NASG on I beta-1b in SP.
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study.
Neurology. 2004;63:1788–1795.
e45. Polman CH, O’Connor PW, Havrdova E, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New Engl J Medicine.
2006;354:899–910.
e46. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–1249.
e47. Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial. Ann Neurol. 2007;61:14–24.
e48. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta- 1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology. 2008;7:903–914.
e49. O’Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective,
randomised, multicentre study. Lancet Neurology. 2009;8:889–897.
e50. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome
(PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet.
2009;374:1503–1511.
e51. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New Engl J Medicine. 2010;362:416–426.
e52. Kappos L, Radue E-W, O’Connor P, et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New Engl J Medicine. 2010;362:387–401.
e53. Cohen JA, Barkhof F, Comi G, et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New Engl J Medicine. 2010;362:402–415.
e54. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized Trial of Oral
Teriflunomide for Relapsing Multiple Sclerosis. New Engl J Medicine. 2011;365:1293–
1303.
e55. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
e56. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
e57. Fox RJ, Miller DH, Phillips JT, et al. Placebo-Controlled Phase 3 Study of Oral BG- 12 or Glatiramer in Multiple Sclerosis. New Engl J Med. 2012;367:1087–1097.
e58. Gold R, Kappos L, Arnold DL, et al. Placebo-Controlled Phase 3 Study of Oral BG- 12 for Relapsing Multiple Sclerosis. New Engl J Med. 2012;367:1098–1107.
e59. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, Group GS. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol.
2013;73:705–713.
e60. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology. 2014;13:657–665.
e61. Calabresi PA, Radue E-W, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurology. 2014;13:545–556.
e62. Leist TP, Comi G, Cree BAC, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology. 2014;13:257–267.
e63. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology. 2014;13:977–986.
e64. Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology. 2014;13:247–256.
e65. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New Engl J Medicine. 2015;373:1418–1428.
e66. Cohen J, Belova A, Selmaj K, et al. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Jama Neurol. 2015;72:1–9.
e67. Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
e68. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New Engl J Medicine. 2016;376:221–234.
e69. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New Engl J Medicine. 2016;376:209–220.
e70. Kapoor R, Ho P-R, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3,
randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology. 2018;17:405–415.
e71. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Lancet. 2018;391:1263–1273.
e72. Chitnis T, Arnold DL, Banwell B, et al. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New Engl J Med. 2018;379:1017–1027.
e73. Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler J. Epub 2019.:135245851988176.
e74. Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology. 2019;18:1021–1033.
e75. Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre,
randomised, minimum 12-month, phase 3 trial. Lancet Neurology. 2019;18:1009–1020.
e76. Group TE-M-2 S, Naismith RT, Wundes A, et al. Diroximel Fumarate
Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. Cns Drugs. 2020;34:185–
196.
